[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612925":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":29,"responsibleParty":53,"collaborators":18,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":18,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":77,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multimodal approach","EXPERIMENTAL","The patient will undergo multimodal imaging and biological sampling",[13],"Other: Multimodal approach",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"The patient will undergo MRI, PET\u002Fcan and biological samples",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Lise-Marie Roussel, MD","CONTACT","+33276015781","lise-marie.roussel@chb.unicancer.fr",{"name":26,"role":22,"phone":27,"phoneExt":18,"email":28},"Doriane Richard, PhD","+33232082985","doriane.richard@chb.unicancer.fr",[30,43],{"facility":5,"status":18,"city":31,"state":18,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Rouen","France","FR",{"type":35,"coordinates":36},"Point",[37,38],1.09932,49.44313,{"lat":38,"lon":37},[41],{"name":42,"role":22,"phone":23,"phoneExt":18,"email":24},"Lise-Marie Roussel, Md",{"facility":44,"status":18,"city":31,"state":18,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":45,"geoPoint":47,"contacts":48},"Centre Hospitalier Universitaire",{"type":35,"coordinates":46},[37,38],{"lat":38,"lon":37},[49],{"name":50,"role":22,"phone":51,"phoneExt":18,"email":52},"Sophie Deneuve","+33232888990","sophie.deneuve@chb.unicancer.fr",{"type":54,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100612925","multimodal-prediction-of-response-to-chemoradiotherapy-for-squamous-cell-carcinoma-of-the-head-and-neck-100612925",false,"NCT07259915","Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck","MULTINECK","Inclusion Criteria:\n\n* Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4)\n* With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required)\n* Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg\u002Fm2 every 3 weeks or 40 mg\u002Fm2 weekly)\n* Regardless of p16 status\n* Affiliated with or covered by a social security system\n\nExclusion Criteria:\n\n* Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses)\n* Primary squamous cell carcinoma of the lymph nodes\n* History of radiotherapy to the head and neck region\n* Radiochemotherapy not based on the use of cisplatin\n* Pregnant or breastfeeding women\n* History of invasive cancer in the last 3 years (except for Breslow melanoma less than 1 mm)\n* Contraindication to MRI, CT, or PET\u002FCT\n* Allergy or contraindication to iodine, gadolinium, or 18F-FDG\n* Uncontrolled diabetes (fasting blood glucose greater than 12 mmol\u002Fl)\n* Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographical issues, etc.)\n* Patients under guardianship or conservatorship\n* Patients deprived of their liberty by judicial or administrative decision\n* Patients undergoing psychiatric care that renders them incapable of giving their consent\n* Patients admitted to a health or social care facility for purposes other than research","ALL","18 Years",{"count":65,"type":66},152,"ESTIMATED","INTERVENTIONAL",[69],"NA","The goal of the study lies in offering a multimodal analysis of the post-therapeutic response based on both quantitative parameters and radiomics (CT, MRI, and PET imaging), and on tumor biology, in particular the hypersensitive detection of tumor DNA.",[72],"Squamous Cell Cancer of Head and Neck (SCCHN)",[74,75,76],"multimodal approach","CT DNA","Resonance Magnetic Imaging","NOT_YET_RECRUITING","2025-11-21",{"date":80,"type":81},"2025-12-02","ACTUAL",{"date":83,"type":66},"2025-12-01",{"date":85,"type":66},"2030-08-01",{"name":5,"class":6},2]